MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment. It develops therapeutic product candidates using its antibody-based technology platforms and in partnership with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily against various cancers. Its product candidates include margetuximab, enoblituzumab, MGD006, MGD007, MGD011, MGD009, MGD013, MGD010, teplizumab and MGD014. Its clinical product candidate, margetuximab, is a monoclonal antibody directed against human epidermal growth factor receptor 2, (HER2), including certain types of breast and gastroesophageal cancers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MGNX
- Previous Close: $19.46
- 50 Day Moving Average: $19.36
- 200 Day Moving Average: $25.09
- 52-Week Range: $34,835,000.00 - $14.90
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.78
- P/E Growth: 0.04
- Market Cap: $682.77M
- Outstanding Shares: 34,835,000
- Beta: 2.8
- Net Margins: -55.01%
- Return on Equity: -16.99%
- Return on Assets: -14.99%
Companies Related to MacroGenics:
- Current Ratio: 14.34%
- Quick Ratio: 14.34%
What is MacroGenics' stock symbol?
MacroGenics trades on the NASDAQ under the ticker symbol "MGNX."
Where is MacroGenics' stock going? Where will MacroGenics' stock price be in 2017?
9 analysts have issued 12 month price targets for MacroGenics' shares. Their forecasts range from $21.00 to $52.00. On average, they expect MacroGenics' stock price to reach $34.83 in the next year.
When will MacroGenics announce their earnings?
MacroGenics is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
Who owns MacroGenics stock?
MacroGenics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (15.00%), Interwest Venture Management Co. (3.08%), State Street Corp (2.41%), Eventide Asset Management LLC (2.08%), Pinnacle Associates Ltd. (1.87%) and Franklin Resources Inc. (1.69%). Company insiders that own MacroGenics stock include Ezio Bonvini, Jon Marc Wigginton, Lynn Cilinski and Paulo F Costa.
Who sold MacroGenics stock? Who is selling MacroGenics stock?
MacroGenics' stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Pinnacle Associates Ltd., Allianz Asset Management AG, Oxford Asset Management, Franklin Resources Inc. and Tudor Investment Corp Et Al. Company insiders that have sold MacroGenics stock in the last year include Jon Marc Wigginton and Lynn Cilinski.
Who bought MacroGenics stock? Who is buying MacroGenics stock?
MacroGenics' stock was acquired by a variety of institutional investors in the last quarter, including Interwest Venture Management Co., FMR LLC, Marshall Wace LLP, Arrowstreet Capital Limited Partnership, First Light Asset Management LLC, Artal Group S.A., Opaleye Management Inc. and Two Sigma Investments LP.
How do I buy MacroGenics stock?
Shares of MacroGenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of MacroGenics stock cost?
One share of MacroGenics stock can currently be purchased for approximately $19.60.